Fox Run Management L.L.C. Acquires 13,966 Shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX)

Fox Run Management L.L.C. increased its position in shares of Celldex Therapeutics, Inc. (NASDAQ:CLDX - Free Report) by 149.8% in the 4th quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 23,290 shares of the biopharmaceutical company's stock after acquiring an additional 13,966 shares during the period. Fox Run Management L.L.C.'s holdings in Celldex Therapeutics were worth $589,000 as of its most recent filing with the Securities and Exchange Commission.

A number of other institutional investors have also recently bought and sold shares of CLDX. Wellington Management Group LLP raised its stake in shares of Celldex Therapeutics by 14.5% during the 3rd quarter. Wellington Management Group LLP now owns 9,243,599 shares of the biopharmaceutical company's stock worth $314,190,000 after purchasing an additional 1,167,659 shares in the last quarter. Bellevue Group AG increased its holdings in Celldex Therapeutics by 3.4% in the third quarter. Bellevue Group AG now owns 3,071,615 shares of the biopharmaceutical company's stock worth $104,404,000 after buying an additional 100,000 shares during the last quarter. Geode Capital Management LLC raised its position in Celldex Therapeutics by 0.4% during the third quarter. Geode Capital Management LLC now owns 1,540,513 shares of the biopharmaceutical company's stock valued at $52,372,000 after acquiring an additional 6,557 shares in the last quarter. American Century Companies Inc. lifted its stake in Celldex Therapeutics by 46.5% in the fourth quarter. American Century Companies Inc. now owns 608,457 shares of the biopharmaceutical company's stock valued at $15,376,000 after acquiring an additional 193,093 shares during the last quarter. Finally, Charles Schwab Investment Management Inc. grew its position in Celldex Therapeutics by 1.0% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 544,330 shares of the biopharmaceutical company's stock worth $13,755,000 after acquiring an additional 5,474 shares in the last quarter.

Celldex Therapeutics Stock Down 0.3 %

Shares of CLDX stock traded down $0.05 during trading hours on Friday, reaching $19.93. 673,963 shares of the company's stock were exchanged, compared to its average volume of 863,800. Celldex Therapeutics, Inc. has a fifty-two week low of $18.61 and a fifty-two week high of $47.00. The stock has a market capitalization of $1.32 billion, a P/E ratio of -7.75 and a beta of 1.76. The business has a fifty day moving average price of $21.90 and a 200-day moving average price of $26.44.

Celldex Therapeutics (NASDAQ:CLDX - Get Free Report) last released its earnings results on Thursday, February 27th. The biopharmaceutical company reported ($0.71) EPS for the quarter, beating the consensus estimate of ($0.73) by $0.02. The firm had revenue of $1.18 million during the quarter, compared to analysts' expectations of $1.25 million. Celldex Therapeutics had a negative net margin of 1,544.32% and a negative return on equity of 19.75%. As a group, research analysts expect that Celldex Therapeutics, Inc. will post -2.48 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

Several research firms recently issued reports on CLDX. UBS Group started coverage on shares of Celldex Therapeutics in a research note on Thursday, February 13th. They issued a "buy" rating and a $44.00 price objective for the company. Morgan Stanley began coverage on Celldex Therapeutics in a research report on Thursday, March 20th. They issued an "overweight" rating and a $46.00 price target for the company. The Goldman Sachs Group lowered their price objective on Celldex Therapeutics from $42.00 to $36.00 and set a "neutral" rating on the stock in a report on Monday, March 3rd. HC Wainwright reissued a "buy" rating and issued a $80.00 price objective on shares of Celldex Therapeutics in a research note on Friday, February 28th. Finally, Cantor Fitzgerald reaffirmed an "overweight" rating and set a $67.00 target price on shares of Celldex Therapeutics in a research report on Wednesday, January 29th. Two equities research analysts have rated the stock with a hold rating, six have issued a buy rating and one has issued a strong buy rating to the company's stock. Based on data from MarketBeat.com, the company has an average rating of "Moderate Buy" and an average price target of $54.33.

About Celldex Therapeutics

Celldex Therapeutics, Inc, a biopharmaceutical company, engages in developing therapeutic monoclonal and bispecific antibodies for the treatment of various diseases. Its drug candidates include antibody-based therapeutics to treat patients with inflammatory, allergic, autoimmune, and other devastating diseases.